Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID Reference, 5th edition, 486 pages

Free download


  Lung Cancer

  Free Subscription


Articles published in J Clin Oncol

Retrieve available abstracts of 136 articles:
HTML format



Single Articles


    October 2020
  1. BURNS TF, Borghaei H, Ramalingam SS, Mok TS, et al
    Targeting KRAS-Mutant Non-Small-Cell Lung Cancer: One Mutation at a Time, With a Focus on KRAS G12C Mutations.
    J Clin Oncol. 2020 Oct 26:JCO2000744. doi: 10.1200/JCO.20.00744.
    PubMed    


  2. GOLDBERG SB, Redman MW, Lilenbaum R, Politi K, et al
    Randomized Trial of Afatinib Plus Cetuximab Versus Afatinib Alone for First-Line Treatment of EGFR-Mutant Non-Small-Cell Lung Cancer: Final Results From SWOG S1403.
    J Clin Oncol. 2020 Oct 6:JCO2001149. doi: 10.1200/JCO.20.01149.
    PubMed     Abstract available


    September 2020
  3. WATERHOUSE DM, Garon EB, Chandler J, McCleod M, et al
    Continuous Versus 1-Year Fixed-Duration Nivolumab in Previously Treated Advanced Non-Small-Cell Lung Cancer: CheckMate 153.
    J Clin Oncol. 2020 Sep 10:JCO2000131. doi: 10.1200/JCO.20.00131.
    PubMed     Abstract available


    August 2020
  4. CAMIDGE DR, Kim HR, Ahn MJ, Yang JCH, et al
    Brigatinib Versus Crizotinib in Advanced ALK Inhibitor-Naive ALK-Positive Non-Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial.
    J Clin Oncol. 2020 Aug 11:JCO2000505. doi: 10.1200/JCO.20.00505.
    PubMed     Abstract available


  5. FARJAH F, Grau-Sepulveda MV, Gaissert H, Block M, et al
    Volume Pledge is Not Associated with Better Short-Term Outcomes After Lung Cancer Resection.
    J Clin Oncol. 2020 Aug 7:JCO2000329. doi: 10.1200/JCO.20.00329.
    PubMed     Abstract available


    May 2020
  6. RUDIN CM, Awad MM, Navarro A, Gottfried M, et al
    Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study.
    J Clin Oncol. 2020 May 29:JCO2000793. doi: 10.1200/JCO.20.00793.
    PubMed     Abstract available


  7. RECK M, Wehler T, Orlandi F, Nogami N, et al
    Safety and Patient-Reported Outcomes of Atezolizumab Plus Chemotherapy With or Without Bevacizumab Versus Bevacizumab Plus Chemotherapy in Non-Small-Cell Lung Cancer.
    J Clin Oncol. 2020 May 27:JCO1903158. doi: 10.1200/JCO.19.03158.
    PubMed     Abstract available


  8. KENMOTSU H, Yamamoto N, Yamanaka T, Yoshiya K, et al
    Randomized Phase III Study of Pemetrexed Plus Cisplatin Versus Vinorelbine Plus Cisplatin for Completely Resected Stage II to IIIA Nonsquamous Non-Small-Cell Lung Cancer.
    J Clin Oncol. 2020 May 14:JCO1902674. doi: 10.1200/JCO.19.02674.
    PubMed     Abstract available


    March 2020
  9. NORONHA V, Patil VM, Joshi A, Menon N, et al
    Reply to T. Tanaka et al and F. Liang.
    J Clin Oncol. 2020;38:844-846.
    PubMed    


  10. LIANG F
    Contradiction Between Stated Statistical Analysis Method and Displayed Survival Curves.
    J Clin Oncol. 2020;38:844.
    PubMed    


  11. GADGEEL S, Rodriguez-Abreu D, Speranza G, Esteban E, et al
    Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non-Small-Cell Lung Cancer.
    J Clin Oncol. 2020 Mar 9:JCO1903136. doi: 10.1200/JCO.19.03136.
    PubMed     Abstract available


  12. RAMALINGAM SS, Dahlberg SE
    Reply to N. Hanna et al and L. Xie et al.
    J Clin Oncol. 2020;38:771-772.
    PubMed    


  13. HANNA N, Jalal S
    The Case for Maintenance Pemetrexed Plus Bevacizumab.
    J Clin Oncol. 2020;38:770-771.
    PubMed    


    February 2020
  14. HERBST RS, Garon EB, Kim DW, Cho BC, et al
    Long-Term Outcomes and Retreatment Among Patients With Previously Treated, Programmed Death-Ligand 1Positive, Advanced NonSmall-Cell Lung Cancer in the KEYNOTE-010 Study.
    J Clin Oncol. 2020 Feb 20:JCO1902446. doi: 10.1200/JCO.19.02446.
    PubMed     Abstract available


    January 2020
  15. HANNA NH, Schneider BJ, Temin S, Baker S Jr, et al
    Therapy for Stage IV Non-Small-Cell Lung Cancer Without Driver Alterations: ASCO and OH (CCO) Joint Guideline Update.
    J Clin Oncol. 2020 Jan 28:JCO1903022. doi: 10.1200/JCO.19.03022.
    PubMed     Abstract available


  16. WU YL, Zhong WZ, Yan HH
    Reply to A. Tateishi et al.
    J Clin Oncol. 2020;38:286-287.
    PubMed    


  17. TATEISHI A, Ishiki H, Kubo E, Satomi E, et al
    EMERGING-CTONG 1103: For Achieving High-Quality Evidence in a Randomized Phase II Trial.
    J Clin Oncol. 2020;38:285-286.
    PubMed    


  18. XIE L, Fan X, Qian B
    Maintenance Therapy for Advanced Nonsquamous Non-Small-Cell Lung Cancer: More Questions Than Answers.
    J Clin Oncol. 2020 Jan 2:JCO1902356. doi: 10.1200/JCO.19.02356.
    PubMed    


  19. TANAKA T, Ishiki H, Kubo E, Yokota S, et al
    Is Gefitinib Combined With Platinum-Doublet Chemotherapy a Counterpart to Osimertinib Monotherapy in Advanced EGFR-Mutated Non-Small-Cell Lung Cancer in the First-Line Setting?
    J Clin Oncol. 2020 Jan 2:JCO1902509. doi: 10.1200/JCO.19.02509.
    PubMed    


    December 2019
  20. SETO T, Azuma K, Yamanaka T, Sugawara S, et al
    Randomized Phase III Study of Continuation Maintenance Bevacizumab With or Without Pemetrexed in Advanced Nonsquamous Non-Small-Cell Lung Cancer: COMPASS (WJOG5610L).
    J Clin Oncol. 2019 Dec 27:JCO1901494. doi: 10.1200/JCO.19.01494.
    PubMed     Abstract available


  21. BRADLEY JD, Hu C, Komaki RR, Masters GA, et al
    Long-Term Results of NRG Oncology RTOG 0617: Standard- Versus High-Dose Chemoradiotherapy With or Without Cetuximab for Unresectable Stage III Non-Small-Cell Lung Cancer.
    J Clin Oncol. 2019 Dec 16:JCO1901162. doi: 10.1200/JCO.19.01162.
    PubMed     Abstract available


  22. PILLAI RN, Fennell DA, Kovcin V, Ciuleanu TE, et al
    Randomized Phase III Study of Ganetespib, a Heat Shock Protein 90 Inhibitor, With Docetaxel Versus Docetaxel in Advanced Non-Small-Cell Lung Cancer (GALAXY-2).
    J Clin Oncol. 2019 Dec 12:JCO1900816. doi: 10.1200/JCO.19.00816.
    PubMed     Abstract available


  23. SCHNEIDER BJ, Ismaila N, Aerts J, Chiles C, et al
    Lung Cancer Surveillance After Definitive Curative-Intent Therapy: ASCO Guideline.
    J Clin Oncol. 2019 Dec 12:JCO1902748. doi: 10.1200/JCO.19.02748.
    PubMed     Abstract available


  24. CHO JH, Lim SH, An HJ, Kim KH, et al
    Osimertinib for Patients With Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Multicenter, Open-Label, Phase II Trial (KCSG-LU15-09).
    J Clin Oncol. 2019 Dec 11:JCO1900931. doi: 10.1200/JCO.19.00931.
    PubMed     Abstract available


  25. YANG JCH, Kim SW, Kim DW, Lee JS, et al
    Osimertinib in Patients With Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer and Leptomeningeal Metastases: The BLOOM Study.
    J Clin Oncol. 2019 Dec 6:JCO1900457. doi: 10.1200/JCO.19.00457.
    PubMed     Abstract available


    November 2019
  26. ROTOW JK, Janne PA
    What's Old Is New Again: Revisiting Up-Front Chemotherapy in EGFR-Mutated Non-Small-Cell Lung Cancer.
    J Clin Oncol. 2019 Nov 27:JCO1902724. doi: 10.1200/JCO.19.02724.
    PubMed    


  27. MAZIERES J, Kowalski D, Luft A, Vicente D, et al
    Health-Related Quality of Life With Carboplatin-Paclitaxel or nab-Paclitaxel With or Without Pembrolizumab in Patients With Metastatic Squamous Non-Small-Cell Lung Cancer.
    J Clin Oncol. 2019 Nov 21:JCO1901348. doi: 10.1200/JCO.19.01348.
    PubMed     Abstract available


  28. HOSOMI Y, Morita S, Sugawara S, Kato T, et al
    Gefitinib Alone Versus Gefitinib Plus Chemotherapy for Non-Small-Cell Lung Cancer With Mutated Epidermal Growth Factor Receptor: NEJ009 Study.
    J Clin Oncol. 2019 Nov 4:JCO1901488. doi: 10.1200/JCO.19.01488.
    PubMed     Abstract available


    September 2019
  29. DIRKSEN U, Brennan B, Le Deley MC, Cozic N, et al
    High-Dose Chemotherapy Compared With Standard Chemotherapy and Lung Radiation in Ewing Sarcoma With Pulmonary Metastases: Results of the European Ewing Tumour Working Initiative of National Groups, 99 Trial and EWING 2008.
    J Clin Oncol. 2019 Sep 25:JCO1900915. doi: 10.1200/JCO.19.00915.
    PubMed     Abstract available


    August 2019
  30. SIO TT, Mohindra P, Yu NY, Ashman JB, et al
    The Search for Optimal Stereotactic Body Radiotherapy Dose in Inoperable, Centrally Located Non-Small-Cell Lung Cancer Continues.
    J Clin Oncol. 2019 Aug 29:JCO1901330. doi: 10.1200/JCO.19.01330.
    PubMed    


  31. NORONHA V, Patil VM, Joshi A, Menon N, et al
    Gefitinib Versus Gefitinib Plus Pemetrexed and Carboplatin Chemotherapy in EGFR-Mutated Lung Cancer.
    J Clin Oncol. 2019 Aug 14:JCO1901154. doi: 10.1200/JCO.19.01154.
    PubMed     Abstract available


    July 2019
  32. RAMALINGAM SS, Dahlberg SE, Belani CP, Saltzman JN, et al
    Pemetrexed, Bevacizumab, or the Combination As Maintenance Therapy for Advanced Nonsquamous Non-Small-Cell Lung Cancer: ECOG-ACRIN 5508.
    J Clin Oncol. 2019 Jul 30:JCO1901006. doi: 10.1200/JCO.19.01006.
    PubMed     Abstract available


    June 2019
  33. RICCIUTI B, Dahlberg SE, Adeni A, Sholl LM, et al
    Immune Checkpoint Inhibitor Outcomes for Patients With Non-Small-Cell Lung Cancer Receiving Baseline Corticosteroids for Palliative Versus Nonpalliative Indications.
    J Clin Oncol. 2019 Jun 17:JCO1900189. doi: 10.1200/JCO.19.00189.
    PubMed     Abstract available


  34. ZHONG WZ, Chen KN, Chen C, Gu CD, et al
    Erlotinib Versus Gemcitabine Plus Cisplatin as Neoadjuvant Treatment of Stage IIIA-N2 EGFR-Mutant Non-Small-Cell Lung Cancer (EMERGING-CTONG 1103): A Randomized Phase II Study.
    J Clin Oncol. 2019 Jun 13:JCO1900075. doi: 10.1200/JCO.19.00075.
    PubMed     Abstract available


  35. GARON EB, Hellmann MD, Rizvi NA, Carcereny E, et al
    Five-Year Overall Survival for Patients With Advanced NonSmall-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study.
    J Clin Oncol. 2019 Jun 2:JCO1900934. doi: 10.1200/JCO.19.00934.
    PubMed     Abstract available


  36. RANGACHARI D, Costa DB
    From Hope to Reality: Durable Overall Survival With Immune Checkpoint Inhibitors for Advanced Lung Cancer.
    J Clin Oncol. 2019 Jun 2:JCO1901207. doi: 10.1200/JCO.19.01207.
    PubMed    


    May 2019
  37. GOMEZ DR, Tang C, Zhang J, Blumenschein GR Jr, et al
    Local Consolidative Therapy Vs. Maintenance Therapy or Observation for Patients With Oligometastatic Non-Small-Cell Lung Cancer: Long-Term Results of a Multi-Institutional, Phase II, Randomized Study.
    J Clin Oncol. 2019 May 8:JCO1900201. doi: 10.1200/JCO.19.00201.
    PubMed     Abstract available


    April 2019
  38. PASSARO A, Spitaleri G, Gyawali B, de Marinis F, et al
    Immunotherapy in Non-Small-Cell Lung Cancer Patients With Performance Status 2: Clinical Decision Making With Scant Evidence.
    J Clin Oncol. 2019 Apr 17:JCO1802118. doi: 10.1200/JCO.18.02118.
    PubMed    


  39. BEZJAK A, Paulus R, Gaspar LE, Timmerman RD, et al
    Safety and Efficacy of a Five-Fraction Stereotactic Body Radiotherapy Schedule for Centrally Located Non-Small-Cell Lung Cancer: NRG Oncology/RTOG 0813 Trial.
    J Clin Oncol. 2019 Apr 3:JCO1800622. doi: 10.1200/JCO.18.00622.
    PubMed     Abstract available


    March 2019
  40. SHAW AT, Solomon BJ, Besse B, Bauer TM, et al
    ALK Resistance Mutations and Efficacy of Lorlatinib in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer.
    J Clin Oncol. 2019 Mar 20:JCO1802236. doi: 10.1200/JCO.18.02236.
    PubMed     Abstract available


    February 2019
  41. CAMIDGE DR, Davies KD
    MET Copy Number as a Secondary Driver of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Resistance in EGFR-Mutant Non-Small-Cell Lung Cancer.
    J Clin Oncol. 2019 Feb 27:JCO1900033. doi: 10.1200/JCO.19.00033.
    PubMed    


  42. READY N, Hellmann MD, Awad MM, Otterson GA, et al
    First-Line Nivolumab Plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer (CheckMate 568): Outcomes by Programmed Death Ligand 1 and Tumor Mutational Burden as Biomarkers.
    J Clin Oncol. 2019 Feb 20:JCO1801042. doi: 10.1200/JCO.18.01042.
    PubMed     Abstract available


    January 2019
  43. LAI GGY, Lim TH, Lim J, Liew PJR, et al
    Clonal MET Amplification as a Determinant of Tyrosine Kinase Inhibitor Resistance in Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer.
    J Clin Oncol. 2019 Jan 24:JCO1800177. doi: 10.1200/JCO.18.00177.
    PubMed     Abstract available


  44. LISBERG A, Garon EB
    Does Platinum-Based Chemotherapy Still Have a Role in First-Line Treatment of Advanced Non-Small-Cell Lung Cancer?
    J Clin Oncol. 2019 Jan 24:JCO1801534. doi: 10.1200/JCO.18.01534.
    PubMed    


  45. PIETANZA MC, Diao L, Wang J, Byers LA, et al
    Reply to F. Liang.
    J Clin Oncol. 2019;37:259.
    PubMed    


  46. RECK M, Rodriguez-Abreu D, Robinson AG, Hui R, et al
    Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater.
    J Clin Oncol. 2019 Jan 8:JCO1800149. doi: 10.1200/JCO.18.00149.
    PubMed     Abstract available


    December 2018
  47. MARCOUX N, Gettinger SN, O'Kane G, Arbour KC, et al
    EGFR-Mutant Adenocarcinomas That Transform to Small-Cell Lung Cancer and Other Neuroendocrine Carcinomas: Clinical Outcomes.
    J Clin Oncol. 2018 Dec 14:JCO1801585. doi: 10.1200/JCO.18.01585.
    PubMed     Abstract available


  48. OWONIKOKO TK, Dahlberg SE, Sica GL, Wagner LI, et al
    Randomized Phase II Trial of Cisplatin and Etoposide in Combination With Veliparib or Placebo for Extensive-Stage Small-Cell Lung Cancer: ECOG-ACRIN 2511 Study.
    J Clin Oncol. 2018 Dec 5:JCO1800264. doi: 10.1200/JCO.18.00264.
    PubMed     Abstract available


    November 2018
  49. LIANG F
    Is SLFN11 a Promising Predictive Biomarker of Poly (ADP-ribose) Polymerase Inhibitor Sensitivity in Small-Cell Lung Cancer? Not Yet!
    J Clin Oncol. 2018 Nov 29:JCO1800993. doi: 10.1200/JCO.18.00993.
    PubMed    


  50. PENNELL NA, Neal JW, Chaft JE, Azzoli CG, et al
    SELECT: A Phase II Trial of Adjuvant Erlotinib in Patients With Resected Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer.
    J Clin Oncol. 2018 Nov 16:JCO1800131. doi: 10.1200/JCO.18.00131.
    PubMed     Abstract available


    October 2018
  51. ZENG H, Yuan S, Yu J
    Prophylactic Cranial Irradiation in Non-Small-Cell Lung Cancer: Hope or Hype?
    J Clin Oncol. 2018 Oct 22:JCO1800617. doi: 10.1200/JCO.18.00617.
    PubMed    


  52. ADDEO A, Caparrotti F, Picardi C, Dietrich PY, et al
    Prophylactic Cranial Irradiation in Stage III Non-Small-Cell Lung Cancer: Overall Survival Should Not Necessarily Be the Final End Point.
    J Clin Oncol. 2018 Oct 22:JCO1800461. doi: 10.1200/JCO.18.00461.
    PubMed    


  53. RUSTHOVEN CG
    Prophylactic Cranial Irradiation in Non-Small-Cell Lung Cancer: The Costs Outweigh the Benefits.
    J Clin Oncol. 2018 Oct 22:JCO1800732. doi: 10.1200/JCO.18.00732.
    PubMed    


    September 2018
  54. ZENG L, Yang N, Zhang Y
    Should Crizotinib Take It All in ROS1-Positive Non-Small-Cell Lung Cancer?
    J Clin Oncol. 2018 Sep 13:JCO1800119. doi: 10.1200/JCO.18.00119.
    PubMed    


    August 2018
  55. WU YL, Zhang L, Kim DW, Liu X, et al
    Phase Ib/II Study of Capmatinib (INC280) Plus Gefitinib After Failure of Endothelial Growth Factor Receptor (EGFR) Inhibitor Therapy in Patients With EGFR-Mutated, MET Factor-Dysregulated Non-Small-Cell Lung Cancer.
    J Clin Oncol. 2018 Aug 29:JCO2018777326. doi: 10.1200/JCO.2018.77.7326.
    PubMed     Abstract available


  56. REUNGWETWATTANA T, Nakagawa K, Cho BC, Cobo M, et al
    CNS Response to Osimertinib Versus Standard Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.
    J Clin Oncol. 2018 Aug 28:JCO2018783118. doi: 10.1200/JCO.2018.78.3118.
    PubMed     Abstract available


  57. WANG YN, Yao S, Wang CL, Li MS, et al
    Clinical Significance of 4L Lymph Node Dissection in Left Lung Cancer.
    J Clin Oncol. 2018 Aug 27:JCO2018787101. doi: 10.1200/JCO.2018.78.7101.
    PubMed     Abstract available


  58. DE RUYSSCHER DKM, Decaluwe H
    4L Lymph Node Involvement in Left-Sided Lung Cancer: Unique or Not?
    J Clin Oncol. 2018 Aug 27:JCO2018793299. doi: 10.1200/JCO.2018.79.3299.
    PubMed    


  59. ARBOUR KC, Mezquita L, Long N, Rizvi H, et al
    Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non-Small-Cell Lung Cancer.
    J Clin Oncol. 2018 Aug 20:JCO2018790006. doi: 10.1200/JCO.2018.79.0006.
    PubMed     Abstract available


  60. DEVARAKONDA S, Rotolo F, Tsao MS, Lanc I, et al
    Tumor Mutation Burden as a Biomarker in Resected Non-Small-Cell Lung Cancer.
    J Clin Oncol. 2018 Aug 14:JCO2018781963. doi: 10.1200/JCO.2018.78.1963.
    PubMed     Abstract available


    July 2018
  61. WU YL, Ahn MJ, Garassino MC, Han JY, et al
    CNS Efficacy of Osimertinib in Patients With T790M-Positive Advanced Non-Small-Cell Lung Cancer: Data From a Randomized Phase III Trial (AURA3).
    J Clin Oncol. 2018 Jul 30:JCO2018779363. doi: 10.1200/JCO.2018.77.9363.
    PubMed     Abstract available


  62. GRIDELLI C, Morabito A, Cavanna L, Luciani A, et al
    Cisplatin-Based First-Line Treatment of Elderly Patients With Advanced Non-Small-Cell Lung Cancer: Joint Analysis of MILES-3 and MILES-4 Phase III Trials.
    J Clin Oncol. 2018 Jul 20:JCO2017768390. doi: 10.1200/JCO.2017.76.8390.
    PubMed     Abstract available


    June 2018
  63. DONINGTON JS
    Thoracotomy for Stage I Lung Cancer Resections: A Procedure Past Its Time.
    J Clin Oncol. 2018 Jun 26:JCO2018793042. doi: 10.1200/JCO.2018.79.3042.
    PubMed    


  64. ZWEIG JR, Neal JW
    Infiltrating the Blood-Brain Barrier in ALK-Positive Lung Cancer.
    J Clin Oncol. 2018 Jun 25:JCO2018788554. doi: 10.1200/JCO.2018.78.8554.
    PubMed    


  65. PIETANZA MC, Waqar SN, Krug LM, Dowlati A, et al
    Randomized, Double-Blind, Phase II Study of Temozolomide in Combination With Either Veliparib or Placebo in Patients With Relapsed-Sensitive or Refractory Small-Cell Lung Cancer.
    J Clin Oncol. 2018 Jun 15:JCO2018777672. doi: 10.1200/JCO.2018.77.7672.
    PubMed     Abstract available


  66. MOK TS, Cheng Y, Zhou X, Lee KH, et al
    Improvement in Overall Survival in a Randomized Study That Compared Dacomitinib With Gefitinib in Patients With Advanced Non-Small-Cell Lung Cancer and EGFR-Activating Mutations.
    J Clin Oncol. 2018 Jun 4:JCO2018787994. doi: 10.1200/JCO.2018.78.7994.
    PubMed     Abstract available


  67. PIOTROWSKA Z, Gainor JF
    ARCHER 1050: Hitting an Important Mark in EGFR-Mutant Lung Cancer?
    J Clin Oncol. 2018 Jun 4:JCO2018793059. doi: 10.1200/JCO.2018.79.3059.
    PubMed    


    May 2018
  68. BOFFA DJ, Kosinski AS, Furnary AP, Kim S, et al
    Minimally Invasive Lung Cancer Surgery Performed by Thoracic Surgeons as Effective as Thoracotomy.
    J Clin Oncol. 2018 May 23:JCO2018778977. doi: 10.1200/JCO.2018.77.8977.
    PubMed     Abstract available


  69. DE RUYSSCHER D, Dingemans AC, Praag J, Belderbos J, et al
    Prophylactic Cranial Irradiation Versus Observation in Radically Treated Stage III Non-Small-Cell Lung Cancer: A Randomized Phase III NVALT-11/DLCRG-02 Study.
    J Clin Oncol. 2018 May 22:JCO2017775817. doi: 10.1200/JCO.2017.77.5817.
    PubMed     Abstract available


  70. CAMIDGE DR, Kim DW, Tiseo M, Langer CJ, et al
    Exploratory Analysis of Brigatinib Activity in Patients With Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer and Brain Metastases in Two Clinical Trials.
    J Clin Oncol. 2018 May 16:JCO2017775841. doi: 10.1200/JCO.2017.77.5841.
    PubMed     Abstract available


  71. SOLOMON BJ, Kim DW, Wu YL, Nakagawa K, et al
    Final Overall Survival Analysis From a Study Comparing First-Line Crizotinib Versus Chemotherapy in ALK-Mutation-Positive Non-Small-Cell Lung Cancer.
    J Clin Oncol. 2018 May 16:JCO2017774794. doi: 10.1200/JCO.2017.77.4794.
    PubMed     Abstract available


  72. COPUR MS, Crockett D, Gauchan D, Ramaekers R, et al
    Molecular Testing Guideline for the Selection of Patients With Lung Cancer for Targeted Therapy.
    J Clin Oncol. 2018 May 15:JCO2018788240. doi: 10.1200/JCO.2018.78.8240.
    PubMed    


  73. LEONARDI GC, Gainor JF, Altan M, Kravets S, et al
    Safety of Programmed Death-1 Pathway Inhibitors Among Patients With Non-Small-Cell Lung Cancer and Preexisting Autoimmune Disorders.
    J Clin Oncol. 2018 May 10:JCO2017770305. doi: 10.1200/JCO.2017.77.0305.
    PubMed     Abstract available


  74. RENGAN R, Redman M, Zeng J
    Challenge of Proving the Value of Proton Therapy in an Unselected Patient Population in the Era of Precision Oncology: The Fallacy of a One-Size-Fits-All Strategy in Radiotherapy for Lung Cancer.
    J Clin Oncol. 2018 May 10:JCO2018783803. doi: 10.1200/JCO.2018.78.3803.
    PubMed    


  75. LEE CK, Novello S, Ryden A, Mann H, et al
    Patient-Reported Symptoms and Impact of Treatment With Osimertinib Versus Chemotherapy in Advanced Non-Small-Cell Lung Cancer: The AURA3 Trial.
    J Clin Oncol. 2018 May 7:JCO2017772293. doi: 10.1200/JCO.2017.77.2293.
    PubMed     Abstract available


    April 2018
  76. REINMUTH N, Reck M
    Breaking the Glass Ceiling of Overall Survival in Non-Small-Cell Lung Cancer.
    J Clin Oncol. 2018 Apr 30:JCO2018782102. doi: 10.1200/JCO.2018.78.2102.
    PubMed    


    March 2018
  77. WU YL, Yang JC, Kim DW, Lu S, et al
    Phase II Study of Crizotinib in East Asian Patients With ROS1-Positive Advanced Non-Small-Cell Lung Cancer.
    J Clin Oncol. 2018 Mar 29:JCO2017755587. doi: 10.1200/JCO.2017.75.5587.
    PubMed     Abstract available


  78. GETTINGER S, Horn L, Jackman D, Spigel D, et al
    Five-Year Follow-Up of Nivolumab in Previously Treated Advanced Non-Small-Cell Lung Cancer: Results From the CA209-003 Study.
    J Clin Oncol. 2018 Mar 23:JCO2017770412. doi: 10.1200/JCO.2017.77.0412.
    PubMed     Abstract available


  79. JAGSI R, Griffith KA, Bellon JR, Woodward WA, et al
    Concurrent Veliparib With Chest Wall and Nodal Radiotherapy in Patients With Inflammatory or Locoregionally Recurrent Breast Cancer: The TBCRC 024 Phase I Multicenter Study.
    J Clin Oncol. 2018 Mar 20:JCO2017772665. doi: 10.1200/JCO.2017.77.2665.
    PubMed     Abstract available


  80. LU S, Chang J, Liu X, Shi J, et al
    Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Study of Fruquintinib After Two Prior Chemotherapy Regimens in Chinese Patients With Advanced Nonsquamous NonSmall-Cell Lung Cancer.
    J Clin Oncol. 2018 Mar 12:JCO2017767145. doi: 10.1200/JCO.2017.76.7145.
    PubMed     Abstract available


    February 2018
  81. KALEMKERIAN GP, Narula N, Kennedy EB, Biermann WA, et al
    Molecular Testing Guideline for the Selection of Patients With Lung Cancer for Treatment With Targeted Tyrosine Kinase Inhibitors: American Society of Clinical Oncology Endorsement of the College of American Pathologists/International Association for
    J Clin Oncol. 2018 Feb 5:JCO2017767293. doi: 10.1200/JCO.2017.76.7293.
    PubMed     Abstract available


    January 2018
  82. LIN JJ, Zhu VW, Yoda S, Yeap BY, et al
    Impact of EML4-ALK Variant on Resistance Mechanisms and Clinical Outcomes in ALK-Positive Lung Cancer.
    J Clin Oncol. 2018 Jan 26:JCO2017762294. doi: 10.1200/JCO.2017.76.2294.
    PubMed     Abstract available


  83. STOKES WA, Bronsert MR, Meguid RA, Blum MG, et al
    Post-Treatment Mortality After Surgery and Stereotactic Body Radiotherapy for Early-Stage Non-Small-Cell Lung Cancer.
    J Clin Oncol. 2018 Jan 18:JCO2017756536. doi: 10.1200/JCO.2017.75.6536.
    PubMed     Abstract available


  84. RIZVI H, Sanchez-Vega F, La K, Chatila W, et al
    Molecular Determinants of Response to Anti-Programmed Cell Death (PD)-1 and Anti-Programmed Death-Ligand (PD-L)-Ligand 1 Blockade in Patients With Non-Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing.
    J Clin Oncol. 2018 Jan 16:JCO2017753384. doi: 10.1200/JCO.2017.75.3384.
    PubMed     Abstract available


  85. LIAO Z, Lee JJ, Komaki R, Gomez DR, et al
    Bayesian Adaptive Randomization Trial of Passive Scattering Proton Therapy and Intensity-Modulated Photon Radiotherapy for Locally Advanced Non-Small-Cell Lung Cancer.
    J Clin Oncol. 2018 Jan 2:JCO2017740720. doi: 10.1200/JCO.2017.74.0720.
    PubMed     Abstract available


    December 2017
  86. OBEID R, Pietrzik K
    Smoking, B Vitamins, and Lung Cancer: The Chicken or the Egg Causality Dilemma.
    J Clin Oncol. 2017 Dec 28:JCO2017759472. doi: 10.1200/JCO.2017.75.9472.
    PubMed    


  87. FRANCIS S, Orton A, Stoddard G, Tao R, et al
    Sequencing of Postoperative Radiotherapy and Chemotherapy for Locally Advanced or Incompletely Resected Non-Small-Cell Lung Cancer.
    J Clin Oncol. 2017 Dec 13:JCO2017744771. doi: 10.1200/JCO.2017.74.4771.
    PubMed     Abstract available


    November 2017
  88. VAN HOEF MEHM
    Additional Recommendations for ALK Gene-Rearranged Non-Small-Cell Lung Cancer to the Recently Updated American Society of Clinical Oncology Guideline for Stage IV Non-Small-Cell Lung Cancer.
    J Clin Oncol. 2017 Nov 22:JCO2017758367. doi: 10.1200/JCO.2017.75.8367.
    PubMed    


  89. SCHNEIDER BJ, Daly ME, Kennedy EB, Antonoff MB, et al
    Stereotactic Body Radiotherapy for Early-Stage Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Endorsement of the American Society for Radiation Oncology Evidence-Based Guideline.
    J Clin Oncol. 2017 Nov 6:JCO2017749671. doi: 10.1200/JCO.2017.74.9671.
    PubMed     Abstract available


  90. GROSSO F, Steele N, Novello S, Nowak AK, et al
    Nintedanib Plus Pemetrexed/Cisplatin in Patients With Malignant Pleural Mesothelioma: Phase II Results From the Randomized, Placebo-Controlled LUME-Meso Trial.
    J Clin Oncol. 2017;35:3591-3600.
    PubMed     Abstract available


  91. WHITNEY RL, Bell JF, Tancredi DJ, Romano PS, et al
    Hospitalization Rates and Predictors of Rehospitalization Among Individuals With Advanced Cancer in the Year After Diagnosis.
    J Clin Oncol. 2017;35:3610-3617.
    PubMed     Abstract available


    October 2017
  92. BUTTNER R, Gosney JR, Skov BG, Adam J, et al
    Programmed Death-Ligand 1 Immunohistochemistry Testing: A Review of Analytical Assays and Clinical Implementation in Non-Small-Cell Lung Cancer.
    J Clin Oncol. 2017 Oct 20:JCO2017747642. doi: 10.1200/JCO.2017.74.7642.
    PubMed     Abstract available


  93. HORN L, Spigel DR, Vokes EE, Holgado E, et al
    Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057).
    J Clin Oncol. 2017 Oct 12:JCO2017743062. doi: 10.1200/JCO.2017.74.3062.
    PubMed     Abstract available


  94. SMIT EF, Haanen JBAG
    Pembrolizumab in Small-Cell Lung Cancer: In Search of the Best Biomarker.
    J Clin Oncol. 2017 Oct 10:JCO2017745141. doi: 10.1200/JCO.2017.74.5141.
    PubMed    


  95. NELSON DB, Rice DC, Niu J, Atay S, et al
    Long-Term Survival Outcomes of Cancer-Directed Surgery for Malignant Pleural Mesothelioma: Propensity Score Matching Analysis.
    J Clin Oncol. 2017;35:3354-3362.
    PubMed     Abstract available


  96. MOK TSK, Kim SW, Wu YL, Nakagawa K, et al
    Gefitinib Plus Chemotherapy Versus Chemotherapy in Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer Resistant to First-Line Gefitinib (IMPRESS): Overall Survival and Biomarker Analyses.
    J Clin Oncol. 2017 Oct 2:JCO2017739250. doi: 10.1200/JCO.2017.73.9250.
    PubMed     Abstract available


    September 2017
  97. KUBOTA K, Yoshioka H, Oshita F, Hida T, et al
    Phase III, Randomized, Placebo-Controlled, Double-Blind Trial of Motesanib (AMG-706) in Combination With Paclitaxel and Carboplatin in East Asian Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer.
    J Clin Oncol. 2017 Sep 13:JCO2017727297. doi: 10.1200/JCO.2017.72.7297.
    PubMed     Abstract available


  98. O'NEILL AF, Towbin AJ, Krailo MD, Xia C, et al
    Characterization of Pulmonary Metastases in Children With Hepatoblastoma Treated on Children's Oncology Group Protocol AHEP0731 (The Treatment of Children With All Stages of Hepatoblastoma): A Report From the Children's Oncology Group.
    J Clin Oncol. 2017 Sep 11:JCO2017735654. doi: 10.1200/JCO.2017.73.5654.
    PubMed     Abstract available


  99. LEE JK, Lee J, Kim S, Kim S, et al
    Clonal History and Genetic Predictors of Transformation Into Small-Cell Carcinomas From Lung Adenocarcinomas.
    J Clin Oncol. 2017;35:3065-3074.
    PubMed     Abstract available


  100. KRIS MG, Gaspar LE, Chaft JE, Kennedy EB, et al
    Adjuvant Systemic Therapy and Adjuvant Radiation Therapy for Stage I to IIIA Completely Resected Non-Small-Cell Lung Cancers: American Society of Clinical Oncology/Cancer Care Ontario Clinical Practice Guideline Update.
    J Clin Oncol. 2017;35:2960-2974.
    PubMed     Abstract available


    August 2017
  101. GOVINDAN R, Szczesna A, Ahn MJ, Schneider CP, et al
    Phase III Trial of Ipilimumab Combined With Paclitaxel and Carboplatin in Advanced Squamous Non-Small-Cell Lung Cancer.
    J Clin Oncol. 2017 Aug 30:JCO2016717629. doi: 10.1200/JCO.2016.71.7629.
    PubMed     Abstract available


  102. RAMALINGAM SS, Yang JC, Lee CK, Kurata T, et al
    Osimertinib As First-Line Treatment of EGFR Mutation-Positive Advanced Non-Small-Cell Lung Cancer.
    J Clin Oncol. 2017 Aug 25:JCO2017747576. doi: 10.1200/JCO.2017.74.7576.
    PubMed     Abstract available


  103. BRASKY TM, White E, Chen CL
    Long-Term, Supplemental, One-Carbon Metabolism-Related Vitamin B Use in Relation to Lung Cancer Risk in the Vitamins and Lifestyle (VITAL) Cohort.
    J Clin Oncol. 2017 Aug 22:JCO2017727735. doi: 10.1200/JCO.2017.72.7735.
    PubMed     Abstract available


  104. OTT PA, Elez E, Hiret S, Kim DW, et al
    Pembrolizumab in Patients With Extensive-Stage Small-Cell Lung Cancer: Results From the Phase Ib KEYNOTE-028 Study.
    J Clin Oncol. 2017 Aug 16:JCO2017725069. doi: 10.1200/JCO.2017.72.5069.
    PubMed     Abstract available


  105. HANNA N, Johnson D, Temin S, Baker S Jr, et al
    Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update.
    J Clin Oncol. 2017 Aug 14:JCO2017746065. doi: 10.1200/JCO.2017.74.6065.
    PubMed     Abstract available


  106. IKOMA N, You YN, Bednarski BK, Rodriguez-Bigas MA, et al
    Impact of Recurrence and Salvage Surgery on Survival After Multidisciplinary Treatment of Rectal Cancer.
    J Clin Oncol. 2017;35:2631-2638.
    PubMed     Abstract available


  107. NIPP RD, Greer JA, El-Jawahri A, Moran SM, et al
    Coping and Prognostic Awareness in Patients With Advanced Cancer.
    J Clin Oncol. 2017;35:2551-2557.
    PubMed     Abstract available


    July 2017
  108. YANG JJ, Yu D, Takata Y, Smith-Warner SA, et al
    Dietary Fat Intake and Lung Cancer Risk: A Pooled Analysis.
    J Clin Oncol. 2017 Jul 25:JCO2017733329. doi: 10.1200/JCO.2017.73.3329.
    PubMed     Abstract available


  109. TAN DSW
    Changing the Natural History of Non-Small-Cell Lung Cancer Through Upfront Programmed Death Protein 1/Programmed Death-Ligand 1 Blockade.
    J Clin Oncol. 2017 Jul 17:JCO2017736215. doi: 10.1200/JCO.2017.73.6215.
    PubMed    


  110. FARAGO AF, Piotrowska Z, Sequist LV
    Unlocking the Mystery of Small-Cell Lung Cancer Transformations in EGFR Mutant Adenocarcinoma.
    J Clin Oncol. 2017 Jul 10:JCO2017735696. doi: 10.1200/JCO.2017.73.5696.
    PubMed    


  111. BENDZSAK AM, Baxter NN, Darling GE, Austin PC, et al
    Regionalization and Outcomes of Lung Cancer Surgery in Ontario, Canada.
    J Clin Oncol. 2017 Jul 6:JCO2016698076. doi: 10.1200/JCO.2016.69.8076.
    PubMed     Abstract available


    June 2017
  112. HAN SS, Rivera GA, Tammemagi MC, Plevritis SK, et al
    Risk Stratification for Second Primary Lung Cancer.
    J Clin Oncol. 2017 Jun 23:JCO2017724203. doi: 10.1200/JCO.2017.72.4203.
    PubMed     Abstract available


  113. BURRIS HA, Infante JR, Ansell SM, Nemunaitis JJ, et al
    Safety and Activity of Varlilumab, a Novel and First-in-Class Agonist Anti-CD27 Antibody, in Patients With Advanced Solid Tumors.
    J Clin Oncol. 2017;35:2028-2036.
    PubMed     Abstract available


  114. PETERS S, Gettinger S, Johnson ML, Janne PA, et al
    Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1-Selected Advanced Non-Small-Cell Lung Cancer (BIRCH).
    J Clin Oncol. 2017 Jun 13:JCO2016719476. doi: 10.1200/JCO.2016.71.9476.
    PubMed     Abstract available


  115. JALAL SI, Lavin P, Lo G, Lebel F, et al
    Carboplatin and Etoposide With or Without Palifosfamide in Untreated Extensive-Stage Small-Cell Lung Cancer: A Multicenter, Adaptive, Randomized Phase III Study (MATISSE).
    J Clin Oncol. 2017 Jun 12:JCO2016717454. doi: 10.1200/JCO.2016.71.7454.
    PubMed     Abstract available


    May 2017
  116. HEIST RS, Guarino MJ, Masters G, Purcell WT, et al
    Therapy of Advanced Non-Small-Cell Lung Cancer With an SN-38-Anti-Trop-2 Drug Conjugate, Sacituzumab Govitecan.
    J Clin Oncol. 2017 May 26:JCO2016721894. doi: 10.1200/JCO.2016.72.1894.
    PubMed     Abstract available


  117. EBERHARDT WEE
    How Should We Choose the Best Therapy for Elderly Patients With Stage III Non-Small-Cell Lung Cancer?
    J Clin Oncol. 2017 May 24:JCO2017729053. doi: 10.1200/JCO.2017.72.9053.
    PubMed    


  118. LIM SM, Kim HR, Lee JS, Lee KH, et al
    Open-Label, Multicenter, Phase II Study of Ceritinib in Patients With Non-Small-Cell Lung Cancer Harboring ROS1 Rearrangement.
    J Clin Oncol. 2017 May 18:JCO2016713701. doi: 10.1200/JCO.2016.71.3701.
    PubMed     Abstract available


  119. OU SI
    Further Advances in the Management of Anaplastic Lymphoma Kinase-Mutated Non-Small-Cell Lung Cancer.
    J Clin Oncol. 2017 May 11:JCO2017731323. doi: 10.1200/JCO.2017.73.1323.
    PubMed    


  120. STINCHCOMBE TE, Zhang Y, Vokes EE, Schiller JH, et al
    Pooled Analysis of Individual Patient Data on Concurrent Chemoradiotherapy for Stage III Non-Small-Cell Lung Cancer in Elderly Patients Compared With Younger Patients Who Participated in US National Cancer Institute Cooperative Group Studies.
    J Clin Oncol. 2017 May 11:JCO2016714758. doi: 10.1200/JCO.2016.71.4758.
    PubMed     Abstract available


  121. EDELMAN MJ, Wang X, Hodgson L, Cheney RT, et al
    Phase III Randomized, Placebo-Controlled, Double-Blind Trial of Celecoxib in Addition to Standard Chemotherapy for Advanced Non-Small-Cell Lung Cancer With Cyclooxygenase-2 Overexpression: CALGB 30801 (Alliance).
    J Clin Oncol. 2017 May 10:JCO2016713743. doi: 10.1200/JCO.2016.71.3743.
    PubMed     Abstract available


  122. POPAT S
    Do Statins Improve Survival in Small-Cell Lung Cancer?
    J Clin Oncol. 2017;35:1497-1498.
    PubMed    


  123. CHALMERS A, Akerley W
    Retrospective, Multi-Institutional Analysis of Sequential Treatment of Brain Metastases in Treatment-Naive, Epidermal Growth Factor Receptor-Mutated Non-Small-Cell Lung Cancer Should Not Define the Standard of Practice.
    J Clin Oncol. 2017 May 8:JCO2017727255. doi: 10.1200/JCO.2017.72.7255.
    PubMed    


  124. KIM DW, Tiseo M, Ahn MJ, Reckamp KL, et al
    Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer: A Randomized, Multicenter Phase II Trial.
    J Clin Oncol. 2017 May 5:JCO2016715904. doi: 10.1200/JCO.2016.71.5904.
    PubMed     Abstract available


  125. GAUTSCHI O, Milia J, Filleron T, Wolf J, et al
    Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global, Multicenter RET Registry.
    J Clin Oncol. 2017;35:1403-1410.
    PubMed     Abstract available


    April 2017
  126. SHEPHERD FA, Lacas B, Le Teuff G, Hainaut P, et al
    Pooled Analysis of the Prognostic and Predictive Effects of TP53 Comutation Status Combined With KRAS or EGFR Mutation in Early-Stage Resected Non-Small-Cell Lung Cancer in Four Trials of Adjuvant Chemotherapy.
    J Clin Oncol. 2017 Apr 28:JCO2016712893. doi: 10.1200/JCO.2016.71.2893.
    PubMed     Abstract available


  127. KAMDAR MK, Smith SM
    Extranodal Marginal Zone Lymphoma: No Longer Just a Sidekick.
    J Clin Oncol. 2017 Apr 27:JCO2017722835. doi: 10.1200/JCO.2017.72.2835.
    PubMed     Abstract available


  128. ZHONG WZ, Liu SY, Wu YL
    Numbers or Stations: From Systematic Sampling to Individualized Lymph Node Dissection in Non-Small-Cell Lung Cancer.
    J Clin Oncol. 2017;35:1143-1145.
    PubMed    


  129. PAGLIARO LC
    Role of High-Dose Chemotherapy With Autologous Stem-Cell Rescue in Men With Previously Treated Germ Cell Tumors.
    J Clin Oncol. 2017;35:1036-1040.
    PubMed     Abstract available


    March 2017
  130. TAYLOR C, Correa C, Duane FK, Aznar MC, et al
    Estimating the Risks of Breast Cancer Radiotherapy: Evidence From Modern Radiation Doses to the Lungs and Heart and From Previous Randomized Trials.
    J Clin Oncol. 2017 Mar 20:JCO2016720722. doi: 10.1200/JCO.2016.72.0722.
    PubMed     Abstract available


  131. SUD A, Thomsen H, Sundquist K, Houlston RS, et al
    Risk of Second Cancer in Hodgkin Lymphoma Survivors and Influence of Family History.
    J Clin Oncol. 2017 Mar 13:JCO2016709709. doi: 10.1200/JCO.2016.70.9709.
    PubMed     Abstract available


  132. TEMEL JS, Greer JA, El-Jawahri A, Pirl WF, et al
    Effects of Early Integrated Palliative Care in Patients With Lung and GI Cancer: A Randomized Clinical Trial.
    J Clin Oncol. 2017;35:834-841.
    PubMed     Abstract available


    February 2017
  133. SPIGEL DR, Edelman MJ, O'Byrne K, Paz-Ares L, et al
    Results From the Phase III Randomized Trial of Onartuzumab Plus Erlotinib Versus Erlotinib in Previously Treated Stage IIIB or IV Non-Small-Cell Lung Cancer: METLung.
    J Clin Oncol. 2017;35:412-420.
    PubMed     Abstract available


    December 2016
  134. NAGTEGAAL ID, Knijn N, Hugen N, Marshall HC, et al
    Tumor Deposits in Colorectal Cancer: Improving the Value of Modern Staging-A Systematic Review and Meta-Analysis.
    J Clin Oncol. 2016 Dec 28:JCO2016689091.
    PubMed     Abstract available


  135. WARDAK Z, Choy H
    Improving Treatment Options for Brain Metastases From ALK-Positive Non-Small-Cell Lung Cancer.
    J Clin Oncol. 2016;34:4064-4065.
    PubMed    


    March 2016
  136. HALABI S, Kelly WK, Ma H, Zhou H, et al
    Meta-Analysis Evaluating the Impact of Site of Metastasis on Overall Survival in Men With Castration-Resistant Prostate Cancer.
    J Clin Oncol. 2016 Mar 7. pii: JCO657270.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Lung Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: